BioXcel Advances Treatment for Agitation in Bipolar Disorders

Progress in the SERENITY At-Home Phase 3 Trial

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a pioneering biopharmaceutical company, has recently announced a key development in its clinical research. This pertains to the completion of the last patient visit in their Phase 3 SERENITY At-Home trial. This clinical trial aims to evaluate the safety and effectiveness of BXCL501, an innovative treatment option for patients experiencing agitation associated with bipolar disorders and schizophrenia.

A Milestone in Agitation Treatment

The SERENITY At-Home Phase 3 trial represents a significant step forward for BioXcel Therapeutics. As the trial wraps up, it has successfully enrolled over 200 patients across 22 sites, all of whom have participated in this double-blind, placebo-controlled study. Patients received a dose of 120 mcg of BXCL501 during periods of agitation, and their safety and response were carefully monitored throughout the 12-week trial period.

Understanding the Need for Home-Based Care

An estimated 23 million episodes of agitation related to bipolar disorder and schizophrenia occur annually in home settings across the United States. Despite this high prevalence, there are currently no FDA-approved treatments for this condition when experienced outside of hospital environments. BioXcel’s efforts aim to fill this critical gap with BXCL501, which could offer much-needed relief for patients facing these challenges.

Insights from the CEO

“This marks a major milestone in our efforts to bring a much-needed at-home (outpatient) treatment option to the millions of individuals who experience agitation related to bipolar disorders or schizophrenia,” stated Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. His commitment to this cause is evident, expressing gratitude to patients, caregivers, and clinical teams who made the continuity of this trial possible.

The SERENITY Trial Design

The design of the SERENITY At-Home trial is crucial in gauging the drug's effectiveness. Patients administered BXCL501 themselves, with the study structured to assess their experience and any side effects through various methods, including the modified Clinical Global Impression scale. This careful approach allows for a comprehensive view of the treatment's impact and its potential for future use in outpatient settings.

About BXCL501

BXCL501, developed by BioXcel Therapeutics, is a sublingual film formulation of dexmedetomidine, a drug originally approved for different medical uses. The focus on its application for outpatient settings adds a layer of innovation to its value proposition. This drug is currently also under investigation for treating agitation in conditions such as Alzheimer’s dementia and has received Breakthrough Therapy designation for its potential uses.

More About IGALMI

IGALMI (dexmedetomidine) is a prescription medication intended for rapid relief of agitation in adults. While it has shown promise for the acute treatment of agitation in specific patient populations, it is important for patients to remain under healthcare supervision while using this medication to monitor vital signs and avoid adverse effects. The safety profile is critical, especially since common side effects include sleepiness, dizziness, and drops in blood pressure.

Important Safety Information

Patients should be aware that IGALMI can lead to serious side effects, including decreased blood pressure and profound drowsiness. Users must refrain from activities that require mental alertness right after administration. Additionally, the medication should be administered under a healthcare provider’s supervision, ensuring appropriate monitoring and guidance.

Conclusion and Future Outlook

With the last patient visit completed, BioXcel Therapeutics prepares for the awaited topline data readout from the SERENITY At-Home trial. This data could potentially pave the way for the submission of a supplemental New Drug Application (sNDA) as part of the company’s strategy for advancing BXCL501 for broader use in home settings for patients suffering from agitation related to bipolar disorders and schizophrenia.

Frequently Asked Questions

1. What is the SERENITY At-Home trial?

The SERENITY At-Home trial is a Phase 3 clinical trial evaluating the safety and effectiveness of BXCL501 for the acute treatment of agitation in bipolar disorders and schizophrenia patients at home.

2. How many patients were involved in the trial?

Over 200 patients participated in the SERENITY At-Home trial across 22 different sites.

3. What is BXCL501?

BXCL501 is an investigational drug formulated as a sublingual film designed to treat agitation, primarily related to bipolar disorders and schizophrenia.

4. What is IGALMI?

IGALMI (dexmedetomidine) is a prescription medication used for the acute treatment of agitation, requiring administration under the supervision of healthcare professionals.

5. What are the common side effects of using IGALMI?

The most common side effects include drowsiness, dizziness, and drops in blood pressure. Patients should consult with their healthcare provider regarding any concerns.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.